Stendra

Shares of biotechnology firm VIVUS (NASDAQ: VVUS) traded lower by almost three percent in Tuesday's after-hours session after the company reported a second-quarter loss of $24 million, or 24 cents a share, compared with a year-earlier loss of $16.2 million, or 20 cents per share. The increase in...

Dear Vivus (NASDAQ: VVUS) investors: You are paying $2.5 billion for a company with zero profits in a market space valued at only $3.5 billion annually. Yes, the FDA advisory committee recommended Qnexa be granted approval in a 20-to-2 vote, but remember that Provenge had a unanimous safety vote...